# A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.

> **NCT02759419** · PHASE4 · COMPLETED · sponsor: **Bayer** · enrollment: 18 (actual)

## Conditions studied

- Hypertension, Pulmonary

## Interventions

- **DRUG:** Adempas (Riociguat, BAY63-2521)

## Key facts

- **NCT ID:** NCT02759419
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-16
- **Primary completion:** 2025-09-15
- **Final completion:** 2025-09-15
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02759419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02759419, "A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02759419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*